Tarsus Names Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

Tarsus Pharmaceuticals has appointed Jeff Farrow as both Chief Financial Officer and Chief Strategy Officer, effective immediately. Farrow replaces Leo Greenstein, who had been CFO since 2020 but is leaving the company to pursue other professional interests.

Farrow has over twenty years of experience in finance and corporate strategy in the life science industry, including leadership roles in several publicly traded commercial biotech companies. Previously, he served as CFO at Global Blood Therapeutics and played a key role in securing regulatory approval and commercializing Oxbryta for the treatment of sickle cell disease. Farrow has also held CFO positions at ZS Pharma and Hyperion Therapeutics.

“I’m delighted to welcome Jeff to Tarsus and look forward to his leadership as we enter the next stage of growth and transition into a commercial organization,” Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus, said in a company news release. “Jeff’s robust experience in finance, corporate strategy and business development – as well as his proven track record in supporting companies as they evolve into successful commercial enterprises – will help position us to transform into a leading eye care company.”

“I’m excited to join Tarsus at this very important and exciting time in the company’s evolution, where we have the opportunity to create and build an entirely new category in eye care and potentially help millions of patients suffering from Demodex blepharitis,” said Mr. Farrow. “I am enthusiastic about joining this extremely talented and motivated team to help take Tarsus to the next level and deliver value to patients and shareholders.”